Sirolimus for treatment of kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon
Authors:
Open Access
- 1 November 2016
- journal article
- Published by Elsevier in JAAD Case Reports
- Vol. 2 (6) , 457-461
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Medication-based therapy of infantile hemangioma and lymphatic malformationsHNO, 2014
- Kaposiform Hemangioendothelioma: Atypical Features and Risks of Kasabach-Merritt Phenomenon in 107 ReferralsThe Journal of Pediatrics, 2013
- Kaposiform Hemangioendothelioma with Kasabach-Merritt Phenomenon: From Vincristine to SirolimusKlinische Padiatrie, 2012
- Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach–Merritt phenomenonPediatric Blood & Cancer, 2012
- Sirolimus for the treatment of complicated vascular anomalies in childrenPediatric Blood & Cancer, 2011
- Treatment of childhood kaposiform hemangioendothelioma with sirolimusPediatric Blood & Cancer, 2010
- Kaposiform hemangioendothelioma (with Kasabach Merritt syndrome) of the head and neck: Case report and review of the literatureInternational Journal of Pediatric Otorhinolaryngology, 2009
- Kaposiform hemangioendotheliomaEuropean Journal of Internal Medicine, 2009
- Kaposiform Hemangioendothelioma: Case Report and Literature ReviewThe Laryngoscope, 2005
- CAPILLARY HEMANGIOMA WITH EXTENSIVE PURPURAA.M.A. American Journal of Diseases of Children, 1940